26.18
Staar Surgical Co stock is traded at $26.18, with a volume of 993.56K.
It is up +3.36% in the last 24 hours and down -4.24% over the past month.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
See More
Previous Close:
$25.33
Open:
$25.15
24h Volume:
993.56K
Relative Volume:
1.08
Market Cap:
$1.30B
Revenue:
$290.38M
Net Income/Loss:
$-21.03M
P/E Ratio:
-60.97
EPS:
-0.4294
Net Cash Flow:
$-54.99M
1W Performance:
+8.14%
1M Performance:
-4.24%
6M Performance:
+62.61%
1Y Performance:
-8.37%
Staar Surgical Co Stock (STAA) Company Profile
Name
Staar Surgical Co
Sector
Industry
Phone
(626) 303-7902
Address
1911 WALKER AVE, MONROVIA, CA
Compare STAA vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
STAA
Staar Surgical Co
|
26.18 | 1.27B | 290.38M | -21.03M | -54.99M | -0.4294 |
|
ISRG
Intuitive Surgical Inc
|
394.51 | 141.76B | 11.03B | 3.16B | 3.22B | 8.7251 |
|
BDX
Becton Dickinson Co
|
183.40 | 50.00B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ALC
Alcon Inc
|
74.25 | 35.57B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
RMD
Resmed Inc
|
224.46 | 32.78B | 5.54B | 1.52B | 1.74B | 10.37 |
|
MDLN
Medline Inc
|
35.74 | 31.15B | 29.14B | 1.07B | 1.05B | 1.1956 |
Staar Surgical Co Stock (STAA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-03-26 | Initiated | Wedbush | Neutral |
| Jan-16-26 | Resumed | Morgan Stanley | Underweight |
| Apr-21-25 | Initiated | Wells Fargo | Equal Weight |
| Feb-12-25 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-12-25 | Downgrade | Jefferies | Buy → Hold |
| Feb-12-25 | Downgrade | Mizuho | Outperform → Neutral |
| Feb-12-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-15-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-11-24 | Upgrade | BTIG Research | Neutral → Buy |
| Mar-11-24 | Upgrade | Stifel | Hold → Buy |
| Dec-05-23 | Downgrade | Needham | Buy → Hold |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-15-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-03-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-07-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-17-23 | Initiated | Piper Sandler | Neutral |
| Feb-06-23 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-28-22 | Reiterated | BTIG Research | Buy |
| Dec-08-22 | Initiated | Stifel | Hold |
| Nov-07-22 | Upgrade | Sidoti | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-28-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jul-09-21 | Initiated | Oppenheimer | Perform |
| Jan-19-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-26-20 | Downgrade | Sidoti | Buy → Neutral |
| Aug-31-20 | Upgrade | Sidoti | Neutral → Buy |
| Aug-06-20 | Reiterated | The Benchmark Company | Buy |
| Jul-06-20 | Downgrade | Sidoti | Buy → Neutral |
| Jun-24-20 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-15-20 | Initiated | Jefferies | Buy |
| Dec-04-19 | Initiated | BTIG Research | Buy |
| Sep-24-18 | Reiterated | The Benchmark Company | Buy |
| Aug-06-18 | Resumed | The Benchmark Company | Buy |
| Nov-20-17 | Reiterated | The Benchmark Company | Buy |
| Aug-14-17 | Reiterated | The Benchmark Company | Buy |
| Mar-03-17 | Reiterated | The Benchmark Company | Buy |
| May-18-16 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-13 | Resumed | The Benchmark Company | Buy |
| Feb-28-13 | Reiterated | The Benchmark Company | Buy |
| Nov-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-02-12 | Initiated | Northland Securities | Outperform |
| Oct-25-11 | Reiterated | The Benchmark Company | Buy |
| Oct-12-10 | Initiated | Morgan Joseph | Buy |
| May-11-10 | Initiated | Benchmark | Buy |
View All
Staar Surgical Co Stock (STAA) Latest News
Staar Surgical Co (STAA) Shares Surge 3.4% -- What GF Score of 80 Tells Investors - GuruFocus
STAAR Surgical (STAA) reports 8.4% stake held by Madison Avenue group - Stock Titan
STAAR Surgical (STAA) Stock Price Shrugs Off Profit Rebound As China Dominates - simplywall.st
Jefferies cuts STAAR Surgical stock price target on estimate update By Investing.com - Investing.com South Africa
STAA Maintains Rating by UBS -- Price Target Lowered to $19.00 - GuruFocus
Jefferies cuts STAAR Surgical stock price target on estimate update - Investing.com
STAA Maintained by Wedbush -- Price Target Lowered to $37.00 - GuruFocus
STAAR Surgical earnings beat by $0.02, revenue topped estimates - Investing.com Australia
Piper Sandler reiterates Neutral on STAAR Surgical stock at $33 By Investing.com - Investing.com South Africa
Piper Sandler reiterates Neutral on STAAR Surgical stock at $33 - Investing.com
Staar Surgical Co (STAA) (Q2 2026) Earnings Call Highlights: Record Revenue Surge and Strategic ... - Yahoo Finance
STAA SWOT Analysis: Strong Financial Recovery Revealed in 10-Q F - GuruFocus
STAA Looks 19.9% Undervalued on GF Value™ - GuruFocus
Why STAAR Surgical (STAA) Is Getting Fresh Attention Now - simplywall.st
Earnings call transcript: STAAR Surgical tops revenue views in Q2 2026 - Investing.com Nigeria
STAAR Surgical Q2 EPS $0.16 beats $0.15 estimate; sales up 111% - scanx.trade
STAAR Surgical (NASDAQ:STAA) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Is Staar Surgical Co (STAA) Undervalued After Q2 Earnings? EPS a - GuruFocus
STAAR Surgical Posts Strong Q2 2026 Earnings, Net Income Surges to $8.1 Million - Kalkine Media
STAAR Surgical Company (STAA) Q2 FY2026 earnings call transcript - Yahoo Finance
STAAR Surgical Q2 2026 Earnings: China Rebound Restores Profitability - tradingkey.com
Earnings Flash (STAA) STAAR Surgical Posts Q2 EPS $0.16, vs. FactSet Est of $0.14 - marketscreener.com
Staar Surgical: Q2 Earnings Snapshot - marketscreener.com
STAAR Surgical (STAA) more than doubles Q2 sales and returns to profit - Stock Titan
STAAR Surgical Reports Second Quarter 2026 Results - Business Wire
STAAR Surgical faces earnings test amid China growth, CEO transition - Investing.com
Defender Capital LLC. Has $12.37 Million Position in STAAR Surgical Company $STAA - MarketBeat
Masimo, Staar Name New Leaders - Orange County Business Journal
Renaissance Technologies LLC Acquires 97,400 Shares of STAAR Surgical Company $STAA - MarketBeat
How Investors Are Reacting To STAAR Surgical (STAA) Formalizing Warren Foust’s CEO Role And Leadership Structure - simplywall.st
Janus Henderson Group PLC Sells 82,283 Shares of STAAR Surgical Company $STAA - MarketBeat
STAAR Surgical Company $STAA Holdings Raised by Dimensional Fund Advisors LP - MarketBeat
Staar Surgical Names Warren Foust Permanent CEO, CFO Promoted - The Globe and Mail
STAA Stock On Track For Its Fourth Straight Session Of Gains – This Analyst Would Rather Be Early Than Late On Staar’s Growth Story - Stocktwits
STAAR Surgical Appoints Warren Foust as Permanent CEO with Detailed Compensation Plan - Kalkine Media
Form 8K STAAR Surgical Company For: 6 August By Investing.com - Investing.com Canada
STAAR Surgical (NASDAQ: STAA) names Warren Foust chief executive - Stock Titan
STAAR Surgical appoints Warren Foust as permanent CEO - MedTech Dive
Staar Appoints Warren Foust as Permanent CEO - Orange County Business Journal
STAAR Surgical Names Warren Foust as Permanent CEO - Medical Product Outsourcing
Staar Surgical Appoints Warren Foust as President and CEO - Eyewire+
Warren Foust Named President and CEO of STAAR Surgical, Deborah Andrews Transitions to Executive Vice President and CFO Roles - VisionMonday.com
STAAR Surgical names Warren Foust CEO, Andrews to EVP and CFO - Investing.com
Staar Surgical picks current COO, former J&J exec as new CEO - MassDevice
STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer - marketscreener.com
STAAR Surgical Company Appoints Warren Foust as Member of Its Board of Directors and Deborah Andrews as Executive Vice President, Effective August 4, 2026 - marketscreener.com
STAAR Surgical to discuss vision correction business Aug. 12 - Stock Titan
STAA Reiterated by Wedbush -- Price Target Maintained at $40 - GuruFocus
STAAR Surgical Company (STAA) Stock Forecasts - Yahoo Finance
STAAR Surgical Co (STAA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
STAA Initiates Coverage On Staar Surgical -- Rating Set to Sell - GuruFocus
Staar Surgical Co Stock (STAA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):